Your current location is:{Current column} >>Text

Amgen to buy Horizon Therapeutics for $26.40 billion By Reuters

{Current column}685People have watched

Introduction(Reuters) -Amgen Inc will buy rare disease drugmaker Horizon Therapeutics (NASDAQ:) Plc for $26.40 b ...

(Reuters) -Amgen Inc will buy rare disease drugmaker Horizon Therapeutics (NASDAQ:) Plc for $26.40 billion,trfx foreign exchange exchange group giving the biotech company access to blockbuster thyroid eye disease drug Tepezza, the companies said on Monday.

The deal will be Amgen (NASDAQ:)'s biggest yet and will add several approved drugs to the company's portfolio including Krystexxa used for the treatment of gout that is not controlled by other medicines.

Amgen to buy Horizon Therapeutics for $26.40 billion By Reuters

The acquisition could help Amgen counter the impact from rising competition for its top-selling arthritis drug, Enbrel, from newer branded treatments and expected expiry of patents for the therapy in 2029.

Statement: The content of this article does not represent the views of FTI website. The content is for reference only and does not constitute investment suggestions. Investment is risky, so you should be careful in your choice! If it involves content, copyright and other issues, please contact us and we will make adjustments at the first time!

Tags:

Related articles